Cheaper Zocor throws generic market a curveball

Employee Benefit Adviser, October, 2006 by Chris Silva

A recent change in policy adopted by large pharmaceutical firm Merck to offer greater discounts for its cholesterol-lowering drug Zocor has given employer-clients, pharmacy benefit managers and insurers a tough benefit design decision: Should they stick with convention and push generic substitution (simvastatin), or offer brand-name Zocor at a lower cost? It's an anomaly for clients used to promoting cheaper generics wherever available.

Rarely have they had to consider whether a cheaper brand-name drug is a better alternative than a generic. The decisions made could have a huge impact on the pharmaceutical industry, which features constant bickering between the generic and brand-name industries over exclusivity and marketing rights, patent law, distribution policies,...

Premium Content Partnership | MyWire provides an in-depth online archive library of reference works. MyWire

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here